- Investing.com
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-7, a potent and selective antagonist of the adenosine A2B receptor; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Metrics to compare | PRTG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRTGPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.0x | −0.6x | −0.5x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price/Book | −111.7x | 1.1x | 2.6x | |
Price / LTM Sales | - | 7.2x | 3.2x | |
Upside (Analyst Target) | - | 197.2% | 42.0% | |
Fair Value Upside | Unlock | 15.0% | 6.6% | Unlock |